Challenges For Bioresorbable Stents In Peripheral Arterial Disease
Executive Summary
Are bioresorbable stents for peripheral arterial disease losing their luster, even before getting to the market? Expectations for drug-eluting balloons seem to be soaring at stent’s expense.
You may also be interested in...
Research Briefs: Abbott Peripheral Stent Data; Biotronik MRI Pacemaker Study
Six-month data from the ESPRIT trial show that Abbott’s Esprit BVS, a peripheral stent based on the same technology as the Absorb BVS, reduces symptoms and keeps arteries open. Biotronik also announced that it has moved into the second phase of an MRI-compatibility trial of its Entovis pacemaker. More research news.
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.